Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries (ZoMaxx™ I)

This study has been completed.
Sponsor:
Information provided by:
Abbott Vascular
ClinicalTrials.gov Identifier:
NCT00148356
First received: September 6, 2005
Last updated: March 31, 2011
Last verified: March 2011

September 6, 2005
March 31, 2011
September 2004
May 2006   (final data collection date for primary outcome measure)
The primary end-point is in-segment late-loss at 9 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD. [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
The primary end-point is in-segment late-loss at 9 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD.
Complete list of historical versions of study NCT00148356 on ClinicalTrials.gov Archive Site
  • Target Lesion revascularization(TLR) [ Time Frame: at 9 months ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: at 9 months ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure [ Time Frame: at 9 months ] [ Designated as safety issue: Yes ]
  • Major Adverse Cardiac Events(MACE) defined as Cardiac Death, MI( Q-wave and non Q-wave) or TVR [ Time Frame: at 30 days, 6,9,12 months and anually through 5 years ] [ Designated as safety issue: Yes ]
The main secondard outcome is angiographic in-stent and in-segment binary restenosis rate (> 50% diameter stenosis) at 9 months post-procedure
Not Provided
Not Provided
 
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions

The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.

Heart disease is the leading cause of death in Europe as a whole, and while mortality rates for cardiovascular disease have decreased in most western European countries, due to expanded use of prevention strategies and better treatment, coronary heart disease mortality in the middle age groups is increasing rapidly in most of the countries in Eastern Europe. The number of procedures performed to treat cardiovascular disease in Europe is constantly increasing, although different types of procedures are exhibiting different trends. Percutaneous coronary interventions (PCI) procedures, for example, totaled 430,000 in the European Union (15 countries) and 520,000 in Europe as a whole (33 countries) in 2000, as reported by the Euro Heart Survey, and growth is continuing at a rate of more than 20% per year. Despite the effectiveness of intracoronary stents in maintaining a larger luminal diameter as compared to angioplasty alone, 15 - 35% of in-stent restenosis occurs within 6 to 9 months after stent placement. While stents can reduce restenosis by blocking vascular recoil and remodeling, mechanical intervention alone is incapable of treating the biological problem of neointimal hyperplasia. Various approaches have been used to treat in-stent restenosis, including balloon angioplasty, repeat stenting, rotational and directional atherectomy, laser and local use of radiation at the time of stenting (brachytherapy). However, these techniques add complexity to the interventional procedure and have not had documented success in preventing restenosis. Drug-eluting stents (DES) using antiproliferative agents delivered via a polymer based stent platform have shown significant success in the reduction of restenosis in de novo lesions over the traditional bare metal stents in randomized clinical trials. Local delivery of the pharmacological agent allows for controlled delivery of high drug concentrations to the targeted tissue while maximizing systemic drug effects. The ZoMaxx I Trial is a study of the ZoMaxx Drug Eluting Coronary Stent System (ZoMaxx DES) to evaluate the potential benefits of the local application of the zotarolimus drug in combination with a phosphorylcholine (PC)-coated tri-metal stent.

ZoMaxx™ Drug-Eluting Stent System is an Investigational device. Limited by Federal (U.S.) law to investigational use only.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Coronary Disease
  • Coronary Artery Disease
  • Coronary Restenosis
  • Device: ZoMaxx™ Drug-Eluting Coronary Stent System
    Drug eluting stent implantation stent in the treatment of coronary artery disease.
  • Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
    Drug eluting stent implantation stent in the treatment of coronary artery disease.
  • Experimental: 1
    ZoMaxx™ Drug-Eluting Stent System
    Intervention: Device: ZoMaxx™ Drug-Eluting Coronary Stent System
  • Active Comparator: 2
    TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
    Intervention: Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
Bernard Chevalier, MD., et. al. A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus-Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial. JACC: Cardiovascular Interventions. 1(5):524-32, 2008.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
401
October 2010
May 2006   (final data collection date for primary outcome measure)

Inclusion Criteria include all of the following:

  • Subject is ≥ 18 years old.
  • Female of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and utilize reliable birth control for nine (9) months after enrollment.
  • Subject is eligible for percutaneous coronary intervention (PCI) and has a single lesion requiring treatment.
  • Subject is an acceptable candidate for CABG.
  • Subject has clinical evidence of ischemic heart disease or a positive functional study.
  • Subject has documented stable angina pectoris

Exclusion Criteria include all of the following:

  • Evidence of an acute myocardial infarction (AMI) or CK-MB > 2x upper limit of normal within 72 hours of the intended treatment (refer to WHO definition).
  • Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, stainless steel, tantalum, contrast agent (that cannot be adequately premedicated), paclitaxel, or drugs similar to ABT-578 (i.e. tacrolimus, sirolimus, everolimus).
  • A platelet count < 100 x 109/L or > 700 x 109/L (< 100,000 cells/mm3 or > 700,000 cells/mm3); a WBC < 3,000 cells/mm3; or a hemoglobin < 10.0 g/dl.
  • Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl or > 150 µmol/L).
  • Subject has had any previous or planned brachytherapy in the target vessel.
  • Target vessel has evidence of thrombus or is excessively tortuous (> 60 degree bend) that makes it unsuitable for proper stent delivery and deployment.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
New Zealand,   United Kingdom,   Belgium,   Germany,   France,   Netherlands,   Switzerland,   Portugal,   Australia,   Denmark
 
NCT00148356
640-0047
Yes
Abbott Vascular
Abbott Vascular
Not Provided
Principal Investigator: Bernard Chevalier, M.D. Centre Cardiologique du Nord
Abbott Vascular
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP